TSH receptor antibodies blood test
TSH receptor antibodies (TRAb, TSI). Also called: TRAb, TSI, TBII, Thyroid-stimulating immunoglobulin, Thyrotropin receptor antibodies, Thyrotropin binding inhibitory immunoglobulin
TSH receptor antibodies switch the thyroid on in Graves' disease, the most common cause of an overactive thyroid. Labcorp reads above 1.75 IU/L as positive and Quest above 2.00 IU/L. They are used for diagnosis, before stopping treatment and in pregnancy.
At a glance
| What it measures | Antibodies against the TSH receptor on thyroid cells. Stimulating ones (TSI) switch the thyroid on and cause Graves' disease; blocking ones switch it off. |
|---|---|
| Two kinds of test | Binding tests (TRAb, TBII) detect both stimulating and blocking antibodies; TSI tests detect only the stimulating ones. |
| Adult cut-offs | Binding: Labcorp 0.0-1.75 IU/L, Quest 2.00 IU/L or lower. TSI: Labcorp 0.00-0.55 IU/L, Quest below 140% of baseline. |
| When it is ordered | To diagnose Graves' disease, before stopping antithyroid drugs, and early in pregnancy in women with past or current Graves' disease. |
| Peptides | No peptide has been shown to change these antibodies. Octreotide and Lanreotide were tried for Graves' eye disease, but those trials reported eye outcomes, not antibody levels. |
| Lab code | LOINC 5385-0 (Labcorp 010314); 40673-6 (Quest 38683); TSI 30567-2 (Labcorp 140749, Quest 30551) |
What are TSH receptor antibodies?
TSH receptor antibodies attach to the receptor that TSH normally uses to switch the thyroid on. Stimulating antibodies mimic TSH and drive the thyroid to make too much hormone: that is Graves' disease, which affects about 0.4% of people in the US. The antibodies can be shown in 90% of people with Graves' disease, and the 2018 European guideline recommends measuring them for diagnosis, before stopping antithyroid drugs and during pregnancy.
How it is made and regulated
Where it is made
The immune system makes IgG antibodies against the TSH receptor. Stimulating antibodies mimic TSH; blocking antibodies stop TSH from binding and can cause an underactive thyroid instead.
What controls it
Several genes raise susceptibility to Graves' disease, and cigarette smoking, high iodine intake, stress and pregnancy all predispose to it.
Sources: [4]
How it travels in the blood
Binding assays measure how much the antibodies block TSH from binding its receptor, so they detect stimulating and blocking antibodies together; with second- and third-generation assays their pooled sensitivity and specificity were 97% and 98%. TSI assays detect only the stimulating ones.
How long it lasts
Antithyroid drugs reduce the antibody level and raise the chance of remission. Remission rates reach their maximum of 50-55% within 12-18 months of treatment.
Sources: [4]
What it does
Stimulating antibodies cause the overactive thyroid of Graves' disease and are a predictive marker for Graves' eye disease. Because they are IgG, they cross the placenta and can cause thyroid overactivity in the fetus or newborn.
Reference ranges
Each lab offers two tests, a binding test and a TSI test, with different cut-offs. Neither lab prints a range for children or pregnancy; pregnancy is a reason to order the test, not a different range.
Labcorp (test 010314)
| Group | Range (IU/L) |
|---|---|
| Reference range (binding TRAb) | 0.0-1.75 |
Printed by Labcorp in units/L, the same as IU/L.
Quest Diagnostics (test 38683)
| Group | Range (IU/L) |
|---|---|
| Reference range (binding TRAb) | 2.00 or lower |
From Quest's test directory.
Labcorp (test 140749)
| Group | Range (IU/L) |
|---|---|
| Reference range (TSI) | 0.00-0.55 |
From Labcorp's test page for 140749.
Quest's TSI test (30551) is a bioassay reported as a percentage of baseline, with below 140% as its reference range. Results from different assays cannot be compared.
Is there an "optimal" range?
There is no "optimal" level: the questions are which test to use and what level matters in treatment and pregnancy.
The lab cut-off
Labcorp 1.75; Quest 2.00 IU/L (binding)
Labcorp 010314 and Quest 38683
Above the cut-off the result is positive.
Normal before stopping treatment
Normal level at 12-18 months
European Thyroid Association (2018)
Normal levels before stopping antithyroid drugs indicate a greater chance of remission; with persistently high levels, treatment can continue with a repeat test after another 12 months, or radioactive iodine or surgery can be chosen.
Sources: [4]
A pregnancy threshold
More than 3 times the cut-off
European Thyroid Association (2018)
If the mother's level stays above 3 times the cut-off, the fetus should be monitored for thyroid dysfunction throughout pregnancy.
Sources: [4]
Binding test or bioassay
Binding 97% sensitive and 98% specific
European Thyroid Association (2018)
Modern binding assays perform well for diagnosis; cell-based bioassays show whether the antibodies stimulate or block.
Sources: [4]
What raises it
| Factor | How | How much |
|---|---|---|
| Graves' diseaseCondition | Stimulating antibodies cause the overactive thyroid; they are found in 90% of people with Graves' disease. | No published magnitude [3] |
| Graves' eye diseaseCondition | Stimulating antibodies are a sensitive, predictive marker for the eye and skin manifestations of Graves' disease. | No published magnitude [4] |
| Postpartum and newborn thyroid diseaseCondition | Quest uses the binding test in neonatal and postpartum thyroid dysfunction as well as Graves' disease. | No published magnitude [5] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Antithyroid drugsMedication | Antithyroid drug treatment reduces TSH receptor antibody levels and raises remission rates. | No published magnitude [4] |
| Later pregnancyPhysiology | Maternal antibodies often fall later in pregnancy, so antithyroid drugs can often be stopped. | No published magnitude [4] |
Peptides that affect TSH receptor antibodies
No published peptide data.
No human study has measured TSH receptor antibodies (TRAb, TSI or TBII) after any of the peptides in our library.
Octreotide and Lanreotide were tested in randomized trials for Graves' eye disease, with mixed results on eye inflammation, but the trials reported eye outcomes, not antibody levels. In 2026 health-record studies, people starting a GLP-1 drug (one study) or Semaglutide (another) were diagnosed with thyroid eye disease less often than people on other diabetes drugs; antibodies were not measured. Case reports describe Graves' disease during Tirzepatide and around GnRH-agonist treatment, but single cases cannot show cause.
Pregnancy hormone Human Chorionic Gonadotropin (hCG) stimulates the TSH receptor directly, without antibodies: that is why thyroid tests can look overactive in early pregnancy, and why TSH receptor antibodies help tell that harmless pattern apart from Graves' disease.
What high or low results can mean
A high result
Above 1.75 IU/L on Labcorp's binding test, above 2.00 IU/L on Quest's, or a positive TSI test is positive. With a low TSH and a high free T4 or T3 it confirms Graves' disease as the cause of an overactive thyroid.
- Graves' disease
- Graves' eye disease
- Past Graves' disease, in remission or treated
A low result
Below the cut-off is negative. In an overactive thyroid this points away from Graves' disease, for example toward thyroiditis or the harmless overactivity of early pregnancy. Before stopping antithyroid drugs, a normal level means a better chance of remission.
- No Graves' disease
- Thyroiditis
- Gestational transient thyrotoxicosis
- Graves' disease in remission
How the test works
| Sample | Serum, 1 mL at both labs for the binding test; Labcorp's TSI test also accepts EDTA or heparin plasma. |
|---|---|
| Fasting | Labcorp lists no fasting requirement. |
| Timing | Ordered when an overactive thyroid is found, before stopping antithyroid drugs, and at the first pregnancy visit in women with thyroid autoimmune disease, then again at 18-22 weeks if raised. |
| Lab differences | Binding tests: ECLIA at Labcorp, ELISA at Quest. TSI: an immunoassay at Labcorp, a cell-based bioassay at Quest reported as a percentage of baseline. Labcorp rejects the binding test from patients on heparin. |
| Retesting | Unlike TPO antibodies, these are worth repeating: before stopping treatment, after another 12 months if still high, and during pregnancy. |
| Labcorp order code | 010314: Thyrotropin Receptor Antibody, Serum |
| Labcorp order code | 140749: Thyroid-stimulating Immunoglobulin (TSI) |
| Quest Diagnostics order code | 38683: TRAb (TSH Receptor Binding Antibody) |
| Quest Diagnostics order code | 30551: TSI (Thyroid Stimulating Immunoglobulin) |
| LOINC codes |
|
History
Graves' disease was the first disease shown to be caused by an antibody that switches a hormone receptor on.
- 1958Adams reports an abnormal thyroid-stimulating factor in the serum of some patients with an overactive thyroid, later called the long-acting thyroid stimulator. [16]
- 1965Sunshine and colleagues track the long-acting thyroid stimulator in newborns with thyroid overactivity passed on from their mothers. [17]
- 2018The European Thyroid Association recommends measuring TSH receptor antibodies to diagnose Graves' disease, before stopping treatment and in pregnancy. [4]
FAQ
What is a normal TSH receptor antibody level?
Below the lab's cut-off. Binding tests: 0.0-1.75 IU/L at Labcorp and 2.00 IU/L or lower at Quest. TSI tests: 0.00-0.55 IU/L at Labcorp and below 140% of baseline at Quest.
What is Graves' disease?
An autoimmune disease in which antibodies switch on the TSH receptor, so the thyroid makes too much hormone. It is the main cause of an overactive thyroid, affecting about 0.4% of people in the US, and can also affect the eyes.
What is the difference between TRAb and TSI?
Binding tests (TRAb, TBII) detect any antibody on the TSH receptor, stimulating or blocking. TSI tests detect only the stimulating antibodies that cause Graves' disease.
Does a positive result mean I have Graves' disease?
With an overactive thyroid, yes: guidelines use these antibodies for the diagnosis, and modern binding tests are 97% sensitive and 98% specific.
Sources: [4]
Why is the test repeated before stopping antithyroid drugs?
Normal levels before stopping indicate a greater chance of remission. Remission rates reach 50-55% within 12-18 months; with persistently high levels, treatment can continue with a repeat test after another 12 months.
Sources: [4]
Do antithyroid drugs lower TSH receptor antibodies?
Yes. Antithyroid drugs reduce the antibody levels and raise remission rates, which is why the level is followed during treatment.
Sources: [4]
Why do these antibodies matter in pregnancy?
They cross the placenta and can make the baby's thyroid overactive. Women with thyroid autoimmune disease should have them measured at the first pregnancy visit and, if raised, again at 18-22 weeks; above 3 times the cut-off, the fetus is monitored.
Can pregnancy itself make thyroid tests look overactive?
Yes. The pregnancy hormone hCG stimulates the TSH receptor directly, so thyroid tests can look overactive in early pregnancy. TSH receptor antibodies help tell this harmless pattern apart from Graves' disease.
How do these antibodies differ from TPO antibodies?
TPO antibodies mark thyroid autoimmunity in general and are not worth repeating. TSH receptor antibodies are specific to Graves' disease, and their level is followed during treatment and pregnancy.
Do any peptides affect TSH receptor antibodies?
None has been shown to. Octreotide and Lanreotide were tried for Graves' eye disease, but the trials reported eye outcomes, not antibody levels; GLP-1 drugs as a group, and Semaglutide in a separate study, were linked to fewer thyroid eye disease diagnoses in health-record studies, without antibody data.
Is there anything to avoid before the test?
Labcorp rejects the binding test from patients on heparin. Labcorp lists no fasting requirement.
Sources: [3]
References
- Labcorp. Test 140749: Thyroid-stimulating Immunoglobulin (TSI). Use, methodology, specimen requirements, reference range and LOINC map. labcorp.com/tests/140749/thyroid-stimulating-immunoglobulin-tsi
- Quest Diagnostics. Test code 30551: TSI (Thyroid Stimulating Immunoglobulin). Test directory: methodology, clinical significance, reference range and LOINC. testdirectory.questdiagnostics.com/test/test-detail/30551/tsi-thyroid-stimulating-immunoglobulin?cc=PHP
- Labcorp. Test 010314: Thyrotropin Receptor Antibody, Serum. Use, methodology, specimen requirements, reference range and LOINC map. labcorp.com/tests/010314/thyrotropin-receptor-antibody-serum
- Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. PMID 30283735
- Quest Diagnostics. Test code 38683: TRAb (TSH Receptor Binding Antibody). Test directory: methodology, clinical significance, reference range and LOINC. testdirectory.questdiagnostics.com/test/test-detail/38683/trab-tsh-receptor-binding-antibody?cc=PHP
- Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab. 2006;91(12):4817-24. PMID 16984988
- Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89(12):5910-5. PMID 15579735
- Wémeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005;90(2):841-8. PMID 15562016
- Chang TC, Liao SL. Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2006;29(5):413-22. PMID 16794364
- Muayad J, Chauhan MZ, Hall LM, et al. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2026. PMID 41949435
- Shlomov T, Nitzan I, Pollack R, et al. Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetes. Can J Ophthalmol. 2026;61(3):665-669. PMID 41620207
- Deto Y, Hasegawa R, Ino S, et al. Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report. Case Rep Endocrinol. 2026;2026:9628050. PMID 42676928
- Fujita Y, Horimukai K, Kiyohara M, et al. De Novo Graves' Disease in a 10-Year-Old Girl Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Idiopathic Central Precocious Puberty: A Case Report. Cureus. 2025;17(6):e85231. PMID 40605880
- Tamaki H, Itoh E, Kaneda T, et al. Crucial role of serum human chorionic gonadotropin for the aggravation of thyrotoxicosis in early pregnancy in Graves' disease. Thyroid. 1993;3(3):189-93. PMID 8257857
- Iijima S. Pitfalls in the assessment of gestational transient thyrotoxicosis. Gynecol Endocrinol. 2020;36(8):662-667. PMID 32301638
- ADAMS DD. The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients. J Clin Endocrinol Metab. 1958;18(7):699-712. PMID 13549548
- Sunshine P, Kusumoto H, Kriss JP. Survival time of circulating long-acting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder. Pediatrics. 1965;36(6):869-76. PMID 5846829
- Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215-28. PMID 24783053
Educational information, not medical advice. Lab ranges and test codes were checked on November 3, 2026. Always use the range printed on your own report, and talk to a clinician about your results.